Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | CPT1A | P50416 | 1/20 | 0.37 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | AHCY | P23526 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1808466 | 1.00 | PRMT5 (0.46) | PRMT5KDM1AOPRD1HDAC8CPT1A | |
| SCHEMBL16519772 | 0.94 | PRMT5 (0.47) | PRMT5KDM1AOPRD1GPR119CHEK2 | |
| SCHEMBL1883135 | 0.89 | PRMT5 (0.42) | PRMT5KDM1AHDAC8F2RL3GPR119 | |
| SCHEMBL1883133 | 0.89 | PRMT5 (0.42) | PRMT5KDM1AHDAC8F2RL3GPR119 | |
| SCHEMBL12653244 | 0.86 | PRMT5 (0.48) | PRMT5KDM1AOPRD1CPT1AF2RL3 | |
| SCHEMBL1805031 | 0.85 | PRMT5 (0.44) | PRMT5OPRD1HDAC8F2RL3GPR119 | |
| SCHEMBL1808726 | 0.85 | PRMT5 (0.44) | PRMT5OPRD1HDAC8F2RL3GPR119 | |
| SCHEMBL1808725 | 0.85 | PRMT5 (0.44) | PRMT5OPRD1HDAC8F2RL3GPR119 | |
| SCHEMBL1805033 | 0.85 | PRMT5 (0.44) | PRMT5OPRD1HDAC8F2RL3GPR119 | |
| SCHEMBL1807303 | 0.83 | MAPT (0.50) | PRMT5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493863-B1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-25 | — | — | EP | disclosed |
| US-8895573-B2 | Phenoxy-substituted pyrimidines as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2014-11-25 | — | — | US | disclosed |
| US-8895573-B2 | Phenoxy-substituted pyrimidines as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2014-11-25 | — | — | US | disclosed |
| US-8895573-B2 | Phenoxy-substituted pyrimidines as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2014-11-25 | — | — | US | disclosed |
| US-20140066422-A1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2014-03-06 | — | — | US | disclosed |
| US-20140066422-A1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2014-03-06 | — | — | US | disclosed |
| US-20140066422-A1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2014-03-06 | — | — | US | disclosed |
| US-8394809-B2 | Phenoxy-substituted pyrimidines as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8394809-B2 | Phenoxy-substituted pyrimidines as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | disclosed |
| EP-2493863-A1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2012-09-05 | — | — | EP | disclosed |
| US-20110105455-A1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105455-A1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2011-05-05 | — | — | US | disclosed |
| WO-2011053701-A1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011053701-A1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066422-A1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | OPRK1, OPRL1, OPRM1 | PRMT5 575/4885KDM1A 1148/4885OPRD1 4/4885 |
| US-20110105455-A1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | OPRK1, OPRL1, OPRM1 | PRMT5 575/4885KDM1A 1148/4885OPRD1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.